These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 23714158)

  • 1. The metabolomic window into hepatobiliary disease.
    Beyoğlu D; Idle JR
    J Hepatol; 2013 Oct; 59(4):842-58. PubMed ID: 23714158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
    Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
    Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
    Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
    Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.
    Malnick SDH; Alin P; Somin M; Neuman MG
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis.
    Hashimoto E; Taniai M; Kaneda H; Tokushige K; Hasegawa K; Okuda H; Shiratori K; Takasaki K
    Alcohol Clin Exp Res; 2004 Aug; 28(8 Suppl Proceedings):164S-168S. PubMed ID: 15318106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.
    Hassan I; Gane E
    Intern Med J; 2019 Nov; 49(11):1405-1411. PubMed ID: 30908822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of non-alcoholic fatty liver disease.
    Bellentani S
    Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.
    Tiniakos DG; Maurício J; Reeves HL
    Adv Exp Med Biol; 2018; 1032():55-69. PubMed ID: 30362090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH.
    Dashek RJ; Diaz C; Chandrasekar B; Rector RS
    Front Endocrinol (Lausanne); 2021; 12():770740. PubMed ID: 34745017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.
    Hyun JY; Kim SK; Yoon SJ; Lee SB; Jeong JJ; Gupta H; Sharma SP; Oh KK; Won SM; Kwon GH; Cha MG; Kim DJ; Ganesan R; Suk KT
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
    Agosti P; Sabbà C; Mazzocca A
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
    PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
    Ertle J; Dechêne A; Sowa JP; Penndorf V; Herzer K; Kaiser G; Schlaak JF; Gerken G; Syn WK; Canbay A
    Int J Cancer; 2011 May; 128(10):2436-43. PubMed ID: 21128245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
    Voiculescu M; Nanau RM; Neuman MG
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD).
    Kragh Petersen S; Bilkei-Gorzo O; Govaere O; Härtlova A
    Scand J Immunol; 2020 Nov; 92(5):e12971. PubMed ID: 32892401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.